Journal: medRxiv
Article Title: a-TIGIT mAb belrestotug in combination with anti-PD1 induces an immunocompetent tumor microenvironment (TME)
doi: 10.1101/2025.07.25.25332187
Figure Lengend Snippet: a. Representative coordinate map depicting the spatial distribution TIGIT+Tregs (red), CD8 proximal to TIGIT+Treg (radius <100um; blue), CD8 distal to TIGIT+Tregs (radius >100um; green). Quantification from paired biopsies of CD8+ cells frequency with a minimum of one Treg in a 100uM radius (statistics: linear mixed model). Dash lines connect paired biopsies, black lines represent the mean. b. Representative coordinate map depicting the spatial distribution and CD8-Treg distance in pre-treatment biopsies. Box plot showing the CD8-Treg distance in pre-treatment biopsies in patients stratified by tumor reduction by RECIST1.1. (statistics: linear mixed model) c. Representative images from CD8/PanCK stanning from different pre-treatment biopsies with inflamed, excluded and desert immunotypes from late-stage cancer patients. Box plot showing the CD8 density (cells/mm2) in pre-treatment biopsies in patients stratified by tumor reduction by RECIST1.1. Statistics: Mann-Whithney U. Bar graph showing frequency of immunotype distribution cases across patients with tumor reduction. Statistics: Fisher exact test. PFS analysis of the patient population stratified by immunotypes. Statistics: cox regression.
Article Snippet: FFPE tissue sections were stained for CD8 and pan-cytokeratin (panCK) using a CD8-panCK duplex chromogenic IHC assay developed and validated by CellCarta (Wilrijk, Belgium).
Techniques: